Mishra Sidharth, Jain Shalini, Agadzi Bryan, Yadav Hariom
USF Center for Microbiome Research, Microbiomes Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Curr Obes Rep. 2025 Apr 10;14(1):32. doi: 10.1007/s13679-025-00624-0.
This review addresses critical gaps in knowledge and provides a literature overview of the molecular pathways connecting gut microbiota dysbiosis to increased intestinal permeability (commonly referred to as "leaky gut") and its contribution to metabolic disorders. Restoring a healthy gut microbiota holds significant potential for enhancing intestinal barrier function and metabolic health. These interventions offer promising therapeutic avenues for addressing leaky gut and its associated pathologies in metabolic syndrome.
In metabolic disorders such as obesity and type 2 diabetes (T2D), beneficial microbes such as those producing short-chain fatty acids (SCFAs) and other key metabolites like taurine, spermidine, glutamine, and indole derivatives are reduced. Concurrently, microbes that degrade toxic metabolites such as ethanolamine also decline, while proinflammatory, lipopolysaccharide (LPS)-enriched microbes increase. These microbial shifts place a higher burden on intestinal epithelial cells, which are in closest proximity to the gut lumen, inducing detrimental changes that compromise the structural and functional integrity of the intestinal barrier. Such changes include exacerbation of tight junction protein (TJP)s dysfunction, particularly through mechanisms such as destabilization of zona occludens (Zo)-1 mRNA or post-translational modifications. Emerging therapeutic strategies including ketogenic and Mediterranean diets, as well as probiotics, prebiotics, synbiotics, and postbiotics have demonstrated efficacy in restoring beneficial microbial populations, enhancing TJP expression and function, supporting gut barrier integrity, reducing leaky gut and inflammation, and ultimately improving metabolic disorders. This review summarizes the mechanisms by which gut microbiota contribute to the development of leaky gut and inflammation associated with metabolic syndrome. It also explores strategies for restoring gut microbiota balance and functionality by promoting beneficial microbes, increasing the production of beneficial metabolites, clearing toxic metabolites, and reducing the proportion of proinflammatory microbes. These approaches can alleviate the burden on intestinal epithelial cells, reduce leaky gut and inflammation, and improve metabolic health.
本综述阐述了知识方面的关键空白,并对将肠道微生物群失调与肠道通透性增加(通常称为“肠漏”)联系起来的分子途径及其对代谢紊乱的影响进行了文献综述。恢复健康的肠道微生物群对于增强肠道屏障功能和代谢健康具有巨大潜力。这些干预措施为解决肠漏及其在代谢综合征中的相关病理问题提供了有前景的治疗途径。
在肥胖和2型糖尿病(T2D)等代谢紊乱中,产生短链脂肪酸(SCFAs)的有益微生物以及牛磺酸、亚精胺、谷氨酰胺和吲哚衍生物等其他关键代谢物减少。同时,降解乙醇胺等有毒代谢物的微生物也减少,而富含促炎脂多糖(LPS)的微生物增加。这些微生物变化给最接近肠腔的肠道上皮细胞带来了更大负担,诱导有害变化,损害肠道屏障的结构和功能完整性。这些变化包括紧密连接蛋白(TJP)功能障碍加剧,特别是通过诸如闭合蛋白(Zo)-1 mRNA不稳定或翻译后修饰等机制。包括生酮饮食和地中海饮食以及益生菌、益生元、合生元和后生元在内的新兴治疗策略已证明在恢复有益微生物群、增强TJP表达和功能、支持肠道屏障完整性、减少肠漏和炎症以及最终改善代谢紊乱方面具有疗效。本综述总结了肠道微生物群导致与代谢综合征相关的肠漏和炎症发展的机制。它还探讨了通过促进有益微生物、增加有益代谢物的产生、清除有毒代谢物以及减少促炎微生物比例来恢复肠道微生物群平衡和功能的策略。这些方法可以减轻肠道上皮细胞的负担,减少肠漏和炎症,并改善代谢健康。